Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer

We hereby present the case of a 55 years old patient with clinical diagnosis of high-risk prostate cancer T2bN1Mo Gleason 9 (4 + 5) treated with androgen deprivation therapy and external beam radiotherapy. Despite treatment, castration levels were not achieved and clinical progression was evidenced...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez Pérez, M., Jiménez Marrero, P., Kim Lee, D., Neumann, M.P., Jorge Pérez, N., Hernández Hernández, C., Hernández Escobar, S., Marrero Domínguez, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397599/
https://www.ncbi.nlm.nih.gov/pubmed/28443242
http://dx.doi.org/10.1016/j.eucr.2017.03.027
Descripción
Sumario:We hereby present the case of a 55 years old patient with clinical diagnosis of high-risk prostate cancer T2bN1Mo Gleason 9 (4 + 5) treated with androgen deprivation therapy and external beam radiotherapy. Despite treatment, castration levels were not achieved and clinical progression was evidenced by the appearance of bone metastases and progression of PSA. After several hormonal treatments without any PSA or testosterone response, surgical castration was performed by bilateral orchiectomy. The pathology results showed an incidental Leydig cell tumor in the right testicle.

Ejemplares similares